Milan, Italy: The colour of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new ...

Please provide your email address to receive an email when new articles are posted on . Patients with more purulent sputum had a higher frequency of exacerbations and hospitalizations over 5 years.

A medical professional explores the management of bronchiectasis exacerbations, detailing the significance of sputum color, the potential for hemoptysis, and the exacerbation of comorbidities such as ...

Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. Pamela J. McShane, MD, explores the clinical ...

Non–cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory condition of the lungs associated with respiratory infections and daily cough and sputum. Non-cystic fibrosis bronchiectasis. Image ...

Nebulized tobramycin significantly reduced the density of Pseudomonas aeruginosa in sputum and improved quality of life for adults with bronchiectasis in a study with more than 300 individuals.

Please provide your email address to receive an email when new articles are posted on . At day 84, researchers found that sputum bacterial load significantly decreased among those receiving 500 mg ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...